384-well format high-throughput machine Search Results


well vario 96/384 channel automated pipettor  (CyBio Inc)
90
CyBio Inc well vario 96/384 channel automated pipettor
Well Vario 96/384 Channel Automated Pipettor, supplied by CyBio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/well vario 96/384 channel automated pipettor/product/CyBio Inc
Average 90 stars, based on 1 article reviews
well vario 96/384 channel automated pipettor - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
1536 well plate formats  (Revvity)
90
Revvity 1536 well plate formats
1536 Well Plate Formats, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/1536 well plate formats/product/Revvity
Average 90 stars, based on 1 article reviews
1536 well plate formats - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
384-well plates  (Corning Life Sciences)
90
Corning Life Sciences 384-well plates
384 Well Plates, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/384-well plates/product/Corning Life Sciences
Average 90 stars, based on 1 article reviews
384-well plates - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
384 well plates  (Greiner Bio)
97
Greiner Bio 384 well plates
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
384 Well Plates, supplied by Greiner Bio, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/384 well plates/product/Greiner Bio
Average 97 stars, based on 1 article reviews
384 well plates - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
throughput screening hts 384 well imaging plates  (Greiner Bio)
93
Greiner Bio throughput screening hts 384 well imaging plates
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
Throughput Screening Hts 384 Well Imaging Plates, supplied by Greiner Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/throughput screening hts 384 well imaging plates/product/Greiner Bio
Average 93 stars, based on 1 article reviews
throughput screening hts 384 well imaging plates - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
sterile microwell plates  (Greiner Bio)
97
Greiner Bio sterile microwell plates
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
Sterile Microwell Plates, supplied by Greiner Bio, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sterile microwell plates/product/Greiner Bio
Average 97 stars, based on 1 article reviews
sterile microwell plates - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
cellcarrier ultra imaging plates  (Revvity)
91
Revvity cellcarrier ultra imaging plates
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
Cellcarrier Ultra Imaging Plates, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cellcarrier ultra imaging plates/product/Revvity
Average 91 stars, based on 1 article reviews
cellcarrier ultra imaging plates - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier
magbeads fastdna kit for soil  (Valiant Co Ltd)
96
Valiant Co Ltd magbeads fastdna kit for soil
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
Magbeads Fastdna Kit For Soil, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/magbeads fastdna kit for soil/product/Valiant Co Ltd
Average 96 stars, based on 1 article reviews
magbeads fastdna kit for soil - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
high throughput 384 well format  (Greiner Bio)
95
Greiner Bio high throughput 384 well format
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
High Throughput 384 Well Format, supplied by Greiner Bio, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high throughput 384 well format/product/Greiner Bio
Average 95 stars, based on 1 article reviews
high throughput 384 well format - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
3705 plates  (Corning Life Sciences)
90
Corning Life Sciences 3705 plates
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
3705 Plates, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3705 plates/product/Corning Life Sciences
Average 90 stars, based on 1 article reviews
3705 plates - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
384 well plates  (Tecan Systems)
96
Tecan Systems 384 well plates
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
384 Well Plates, supplied by Tecan Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/384 well plates/product/Tecan Systems
Average 96 stars, based on 1 article reviews
384 well plates - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
384-well high-throughput assay panels  (Biomol GmbH)
90
Biomol GmbH 384-well high-throughput assay panels
Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto <t>384-well</t> plates pre-printed with <t>the</t> <t>384-compound</t> Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.
384 Well High Throughput Assay Panels, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/384-well high-throughput assay panels/product/Biomol GmbH
Average 90 stars, based on 1 article reviews
384-well high-throughput assay panels - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto 384-well plates pre-printed with the 384-compound Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.

Journal: Frontiers in Oncology

Article Title: The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

doi: 10.3389/fonc.2019.01301

Figure Lengend Snippet: Experimental layout. U-2932 and RIVA cells were treated with 1 or 0.5 μg/mL 177 Lu-lilotomab satetraxetan (600 MBq/mg) for 18 h, excess 177 Lu-lilotomab satetraxetan removed, and cells seeded onto 384-well plates pre-printed with the 384-compound Cambridge Cancer compound library sourced from Selleckchem at final concentrations of 10 nM, 100 nM, or 1 μM. Untreated control cells were seeded on parallel plates. Viability measurements, using RealTime-Glo, were carried out between day 3 and 6 after seeding. Inhibitory compounds were considered as candidate hits if they: (1) in combination with 177 Lu-lilotomab satetraxetan inhibited cell proliferation over two consecutive days to a degree greater than the expected additive effect of the mono-treatments alone (BLISS theorem, see Materials and Methods for details), and (2) drug treatment alone did not reduce viability to <90% of that of untreated control.

Article Snippet: The Selleck Cambridge Cancer Compound library was obtained from and printed onto 384-well plates [384 well, PS, F-bottom, μclear, white, lid, sterile, Greiner Bio-One 781098 (82050-076)] by the High-Throughput Chemical Biology Screening Platform at the Center for Molecular Medicine Norway (NCMM).

Techniques: